Metodbevispost

Bayesian Phase I clinical trial

A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.

Sources recorded, not reviewed

Källpost

Citat kopierade ordagrant från metodens källpost. Ingen verifiering på källnivå härleds från dem.

Bayesian Phase I Clinical Trial (Dose-Finding Design)

Taxonomisk metodpost · process-pipeline / epidemiology

O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628
Chevret, S. (Ed.). (2006). Statistical Methods for Dose-Finding Experiments. Wiley. · ISBN 978-0470861769

Öppna fullständig metod

Kuraterade påståenden

Påståenden lagrade i bevisloggen, var och en med sin egen bedömning.

Inga kuraterade påståenden ännu

Denna vy hittar inte på en påståendebedömning när loggen saknar en.

Relaterade metoder

Genererade från metodgrafen och visade som maskinföreslagna relationer – inga bevispåståenden härleds.

Taxonomic bucketAdaptive Phase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketAdaptive Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketBayesian Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketDose-Response Analysismachine-suggested · Relational suggestion, not evidence.Taxonomic bucketPhase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.